Prominent response to platinum-based chemotherapy in a patient with BRCA2 mutant-neuroendocrine prostate cancer and MDM2 amplification

Tatsuaki Daimon, Takeo Kosaka, Hiroshi Hongo, Eriko Aimono, Kohei Nakamura, Shuji Mikami, Hiroshi Nishihara, Mototsugu Oya

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Introduction: Genomic profiling provides useful information for diagnosis, treatment, and prognosis, and detection of certain defects, such as DNA repair gene aberrations or microsatellite instability, can possibly lead to optimal treatment, but this testing has not been widely used to inform prostate cancer treatment. Case presentation: A 55-year-old man sequentially treated for prostate cancer was diagnosed as neuroendocrine prostate cancer from prostate specimens resected because of urinary retention. Subsequently, he received five cycles of platinum-based chemotherapy in total and responded well. We also performed next-generation sequencing of a sample from the prostate specimen and identified a breast cancer susceptibility gene mutation with Murine Double Minute 2 amplification and loss of heterozygosity in retinoblastoma 1. Conclusion: We report a neuroendocrine prostate cancer patient with Murine Double Minute 2 amplification who experienced an aggressive course and for whom platinum-based chemotherapy was effective, and one of the reasons for the good response might be the breast cancer susceptibility gene mutation.

Original languageEnglish
Pages (from-to)216-219
Number of pages4
JournalIJU Case Reports
Volume4
Issue number4
DOIs
Publication statusPublished - 2021 Jul
Externally publishedYes

Keywords

  • BRCA2
  • MDM2
  • genomic profiling
  • neuroendocrine prostate cancer

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Prominent response to platinum-based chemotherapy in a patient with BRCA2 mutant-neuroendocrine prostate cancer and MDM2 amplification'. Together they form a unique fingerprint.

Cite this